Pancreatic Cancer Research

ResearcherTokai UniversityActive in the last 2 years

Toshio Nakagohri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6843-8891; OpenAlex author ID A5013987953, A5085631531. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers

Papers 14

  1. Evaluation of pancreatic elastase-1 measurement during health checkups for detection of pancreatic cancer in asymptomatic individuals. Co-author DOI 10.1016/j.ctarc.2025.100951↗
  2. Low Pretreatment CALLY Index Predicts Early Recurrence in Resected UICC Stage I Pancreatic Ductal Adenocarcinoma. Last author PMID 40105230↗
  3. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  4. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocar… Last author DOI 10.5009/gnl220311↗
  5. miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation. Co-author DOI 10.1038/s41598-022-22950-2↗
  6. Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2020-207002↗
  7. Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study. Last author DOI 10.1186/s12893-021-01236-w↗
  8. [Multidisciplinary Therapy for Unresectable Pancreatic Cancer]. Last author PMID 33130694↗
  9. Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00595-017-1618-3↗
  10. Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report. Last author DOI 10.1186/s40792-018-0522-4↗
  11. Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2016-204028↗
  12. Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis. Last author DOI 10.1007/s00595-015-1126-2↗
  13. Positive Intraoperative Peritoneal Lavage Cytology is a Negative Prognostic Factor in Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Study. Co-author DOI 10.3389/fonc.2015.00182↗
  14. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Co-author DOI 10.1097/mpa.0b013e318215010c↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taro Mashiko · 5 shared papers, 2018–2025 · strength 0.85
  2. Kenichi Hirabayashi · 7 shared papers, 2015–2022 · strength 0.64
  3. Naoya Nakamura · 6 shared papers, 2015–2022 · strength 0.56
  4. Shigenori Ei · 2 shared papers, 2023–2025 · strength 0.47
  5. Shinichiro Takahashi · 2 shared papers, 2023–2025 · strength 0.47
  6. Aya Kawanishi · 4 shared papers, 2017–2022 · strength 0.44
  7. Haruka Itoh · 1 shared paper, 2025 · strength 0.30
  8. Hayato Miyachi · 1 shared paper, 2025 · strength 0.30
  9. Tsubasa Saika · 2 shared papers, 2021–2022 · strength 0.29
  10. Masashi Morimachi · 2 shared papers, 2021–2022 · strength 0.29
  11. Misuzu Yamada · 4 shared papers, 2015–2018 · strength 0.27
  12. Masaki Mori · 1 shared paper, 2025 · strength 0.26
  13. Tetsuya Mine · 3 shared papers, 2015–2018 · strength 0.20
  14. Masaki Miyazawa · 1 shared paper, 2022 · strength 0.16
  15. Hideki Izumi · 2 shared papers, 2015–2018 · strength 0.15
  16. Tatehiro Kagawa · 1 shared paper, 2021 · strength 0.13
  17. Kentaro Sudo · 1 shared paper, 2023 · strength 0.12
  18. Satoaki Nakamura · 1 shared paper, 2023 · strength 0.12
  19. Naoya Kato · 1 shared paper, 2023 · strength 0.12
  20. Nobumasa Mizuno · 1 shared paper, 2023 · strength 0.12
  21. Tatsuya Ioka · 1 shared paper, 2023 · strength 0.12
  22. Satoshi Kobayashi · 1 shared paper, 2023 · strength 0.12
  23. Hiroshi Ishii · 1 shared paper, 2023 · strength 0.12
  24. Masafumi Ikeda · 1 shared paper, 2023 · strength 0.12
  25. Naohiro Okano · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.